Market Research Logo

Europe Viral Vector Vaccine Manufacture Market Forecast 2019-2027

Europe Viral Vector Vaccine Manufacture Market Forecast 2019-2027

KEY FINDINGS

The European viral vector vaccine manufacturing market is expected to have a CAGR of 18.23% during the forecast period of 2019-2027. Growing R&D expenditure for the viral vector vaccines is adding growth to the viral vector vaccine manufacturing market in this region.

MARKET INSIGHTS

Growing R&D expenditure for viral vectors and the growing number of livestock diseases are propelling the viral vector vaccine manufacturing market in Europe. In February 2017, France-based Company Novasep announced an investment of about $xx million for a viral vector production facility. A rise in the HPAI outbreaks in domestic birds in the region is also fueling the adoption of viral-vector-based vaccines, thereby driving the market. A growing number of HIV patients and chronic diseases are also contributing to the growth in the viral vector vaccine manufacturing market in this region.

COMPETITIVE INSIGHTS

Prominent companies involved in the manufacture of viral vector vaccines in the European market are Advanced Biotherapeutics Consulting, Janssen Pharmaceutical Inc., Id Pharma Co. Ltd., Benitec Biopharma, Brammer Bio, Ceva Corporate, Biovian, Cobra Biologics (Subsidiary Of Recip Ab), Boehringer Ingelheim Gmbh, Cell And Gene Therapy Catapult, Batavia Biosciences, Biogen Idec (Now Biogen Inc.), Advanced Bioscience Laboratories Inc., Applied Viromics and Ge Healthcare.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Pox Virus Constitutes The Largest Market Share In Terms Of Types
3.2.2. Human Diseases Are Anticipated To Grow Significantly During The Forecast Period
3.2.3. Multivalent Applications Are Widely Used In The Viral Vector Manufacturing Market
4. Market Determinants
4.1. Market Drivers
4.1.1. Promising Results From Several Clinical Studies
4.1.2. Mounting Number Of Viral Vectors Gene-therapy-based Clinical Trials
4.1.3. Growing Chronic Diseases
4.2. Market Opportunities
4.2.1. Swelling Investment In Gene-therapy-based R&D Activities
4.2.2. Increase In The Research And Development
4.3. Market Restraints
4.3.1. Poor Reimbursement System
4.3.2. Stringent Government Policies
4.4. Market Challenges
4.4.1. Unfavourable Compensation Situation
4.4.2. Pricing Pressure Coupled With Lack Of Product Differentiation
4.4.3. Rigorous Regulatory Agenda
5. Market Segmentation
5.1. Market By Types 2019-2027
5.1.1. Adenoviral Vectors
5.1.2. Retroviral Vectors
5.1.3. Lentiviral Vectors
5.1.4. Adeno-associated Viral Vectors
5.1.5. Poxvirus
5.1.6. Cytomegalovirus
5.1.7. Other Viral Vectors
5.2. Market By Application 2019-2027
5.2.1. Multivalent
5.2.2. Multipathogen
5.3. Market By Diseases 2019-2027
5.3.1. Human Diseases
5.3.1.1. Hepatitis
5.3.1.2. Cancer
5.3.1.3. Malaria
5.3.1.4. Tuberculosis
5.3.1.5. Influenza
5.3.1.6. Hiv
5.3.1.7. Other Human Diseases
5.3.2. Veterinary Diseases
5.3.2.1. Avian Influenza
5.3.2.2. Marek's Disease
5.3.2.3. Infectious Bronchitis
5.3.2.4. Ppr Disease
5.3.2.5. Other Veterinary Diseases
6. Key Analytics
6.1. Evolution And Transition
6.2. Regulatory Framework
6.2.1. European Union
6.3. Key Properties Of Viral Vector
6.4. Characteristics Of Potential Viral Vaccine Vectors
6.5. Patent Analysis
6.5.1. Europe Patent Analysis
6.6. Manufacturing Process Of A Viral-vector
6.7. Small-scale Manufacturing Process Of Adenovirus
6.8. Key Suppliers In Viral Vector Market
6.9. Key Buying Criteria
7. Geographical Analysis
7.1. Europe
7.1.1. Germany
7.1.2. The United Kingdom
7.1.3. France
7.1.4. Spain
7.1.5. Italy
7.1.6. Rest Of The Europe
8. Company Profiles
8.1. Advanced Biotherapeutics Consulting
8.2. Advanced Bioscience Laboratories Inc.
8.3. Applied Viromics
8.4. Batavia Biosciences
8.5. Benitec Biopharma
8.6. Biogen Idec (Now Biogen Inc.)
8.7. Biovian
8.8. Brammer Bio
8.9. Boehringer Ingelheim Gmbh
8.10. Cell And Gene Therapy Catapult
8.11. Ceva Corporate
8.12. Cobra Biologics (Subsidiary Of Recip Ab)
8.13. Ge Healthcare
8.14. Janssen Pharmaceutical Inc.
8.15. Id Pharma Co. Ltd.
Table List
Table 1 Europe Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousand)
Table 2 Ongoing Clinical Trials Related To Viral Vectors
Table 3 Various Viral Vectors Properties And Their Application In Gene Therapy
Table 4 Europe Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 5 Key Viral Vectors Characteristics
Table 6 Europe Viral Vector Vaccine Manufacturing Market In Adenoviral Vectors 2019-2027 ($ Thousands)
Table 7 Europe Viral Vector Vaccine Manufacturing Market In Retroviral Vectors 2019-2027 ($ Thousands)
Table 8 Advantages And Disadvantages Of Retroviral Vectors
Table 9 Components Of Hiv Provirus
Table 10 Europe Viral Vector Vaccine Manufacturing Market In Lentiviral Vectors 2019-2027 ($ Thousands)
Table 11 Second- Vs. Third-generation Lentiviral Systems
Table 12 Aav Vectors With Their Tropisms And Receptors
Table 13 Europe Viral Vector Vaccine Manufacturing Market In Adeno-associated Viral Vectors 2019-2027 ($ Thousands)
Table 14 Licensed Fowl Pox Viral-vectored Veterinary Vaccines
Table 15 Europe Viral Vector Vaccine Manufacturing Market In Pox Virus 2019-2027 ($ Thousands)
Table 16 Europe Viral Vector Vaccine Manufacturing Market In Cytomegalovirus 2019-2027 ($ Thousands)
Table 17 Europe Viral Vector Vaccine Manufacturing Market In Other Viral Vectors 2019-2027 ($ Thousands)
Table 18 Europe Viral Vector Vaccine Manufacturing Market By Application 2019-2027 ($ Thousands)
Table 19 Europe Viral Vector Vaccine Manufacturing Market In Multivalent 2019-2027 ($ Thousands)
Table 20 Tb Statistics For 2016
Table 21 Europe Viral Vector Vaccine Manufacturing Market In Multipathogen 2019-2027 ($ Thousands)
Table 22 Europe Viral Vector Vaccine Manufacturing Market By Diseases 2019-2027 ($ Thousands)
Table 23 Europe Viral Vector Vaccine Manufacturing Market In Human Diseases 2019-2027 ($ Thousands)
Table 24 Europe Viral Vector Vaccine Manufacturing Market In Human Diseases By Types 2019-2027 ($ Thousands)
Table 25 Europe Human Diseases Market In Hepatitis 2019-2027 ($ Thousands)
Table 26 Estimated Actual New Cases Of Hav
Table 27 Europe Human Diseases Market In Cancer 2019-2027 ($ Thousands)
Table 28 Europe Human Diseases Market In Malaria 2019-2027 ($ Thousands)
Table 29 Malaria Vaccine Development Initiatives
Table 30 Viral Vector Vaccine Candidates For Tuberculosis
Table 31 Europe Human Diseases Market In Tuberculosis 2019-2027 ($ Thousands)
Table 32 Europe Human Diseases Market In Influenza 2019-2027 ($ Thousands)
Table 33 Benefits And Concern For Virus-vectored Experimental Influenza Vaccines
Table 34 Europe Human Diseases Market In Hiv 2019-2027 ($ Thousands)
Table 35 Europe Human Diseases Market In Other Human Diseases 2019-2027 ($ Thousands)
Table 36 Ongoing Clinical Trials And Development In Zika Virus Vaccine
Table 37 Licensed Viral-vectored Veterinary Vaccines
Table 38 Europe Viral Vector Vaccine Manufacturing Market In Veterinary Diseases 2019-2027 ($ Thousands)
Table 39 Europe Viral Vector Vaccine Manufacturing Market In Veterinary Diseases By Types 2019-2027 ($ Thousands)
Table 40 Avian Influenza Vaccines
Table 41 Europe Veterinary Diseases Market In Avian Influenza 2019-2027 ($ Thousands)
Table 42 Europe Veterinary Diseases Market In Marek's Disease 2019-2027 ($ Thousands)
Table 43 Marek’s Disease Vaccines
Table 44 Europe Veterinary Diseases Market In Infectious Bronchitis 2019-2027 ($ Thousands)
Table 45 Europe Veterinary Diseases Market In Ppr Disease 2019-2027 ($ Thousands)
Table 46 Europe Veterinary Diseases Market In Other Veterinary Diseases 2019-2027 ($ Thousands)
Table 47 Europe Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Table 48 Germany Viral Vector Vaccine Manufacturing Market 2019-2027 By Types ($ Thousands)
Table 49 The United Kingdom Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 50 France Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 51 Spain Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 52 Italy Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Figures List
Figure 1 Europe Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousand)
Figure 2 Schematic Overview Of Multivalent And Multipathogen Viral Vector Vaccines
Figure 3 Estimation Of People Living With Hiv 2016 (Million)
Figure 4 Prevalence Of Hbv Infection In The General Population 2015 (Millions)
Figure 5 Vaccine Advancements Timeline
Figure 6 Steps Requirement For Vaccine Approval
Figure 7 Vaccine Review And Regulation Steps Under Ema
Figure 8 Manufacturing Process Of Adenovirus
Figure 9 Germany Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 10 The United Kingdom Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 11 Number Of People Living With Hiv In France
Figure 12 France Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 13 Leading Causes Of Women Death In France (%)
Figure 14 Leading Causes Of Men Death In France (%)
Figure 15 Spain Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 16 Number Of People In Spain Infected With Hiv
Figure 17 Italy Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 18 Rest Of The Europe Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 19 Number Of People In Rest Of Europe Infected With Hiv (Thousands)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report